GLG News by Cubicin Prescribers (US)

Peter BornsteinEpidemiologist HEALTHEAST CARE SYSTEM

Documenting What We Knew All Along

July 13, 2011

Analysis of:A Little Placebo Effect For the Common Cold | online.wsj.com

This article from the Wall Street Journal discusses a randomized, double-blind placebo controlled trial on the effectiveness of echinacea and placebo for the common cold. Unsurprisingly, it demonstrated that taking a pill--any pill, including a placebo--reduces symptom severity and duration, compared to "doing nothing."

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

New Agents in Melanoma Show Advances at ASCO

June 9, 2011

Analysis of:Drugs Show Promise Slowing Advanced Melanoma | www.nytimes.com

Data presented a the ASCO meeting showed an overall survival benefit for patients receiving Roche/Genentech's vemurafenib and Bristol-Myers Squibb/s Yervoy (ipilimumab) when these agents were compared to standard of care therapy.

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

Long term Revlimid (Celgene) may cause cancer.

December 7, 2010

Analysis of:Celgene shares plummet on Revlimid malignancy data | www.reuters.com

Data presented at the American Society of Hematology Convention suggests the possibility that long term use of Revlimid may be a associated with the development of secondary malignancies.

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

Outlook is better for Provenge

November 20, 2010

Analysis of:Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com

A Medicare advisory panel gave a lukewarm endorsement to Provenge. Final Medicare opinion is pending.

Daniel BergerClinical Associate Professor of MedicineUNIVERSITY OF ILLINOIS AT CHICAGO

Anticipation Surrounds New Single Regimen Tablet, Containing Rilpivirine for HIV

November 17, 2010

Analysis of:Rilpivirine (TMC 278) in Combination with Truvada is Non-Inferior to an Atripla Like Regimen | positivelyaware.com

It has now been some months since 2010 ICAAC; results of the two phase III trials combined, has been sinking in. Rilpivirine when combined with Truvada (Gilead Sciences) was non- inferior to Atripla (Bristol Myers Squibb and Gilead Sciences). Now the salient details are being put into new perspective. We are about to begin a new trial (phase IV) with this new single-tablet formulation which will add to our body of knowledge and examine further use and importance of this single pill regimen.

Daniel BergerClinical Associate Professor of MedicineUNIVERSITY OF ILLINOIS AT CHICAGO

Egrifta Gains FDA Approval for HIV

November 11, 2010

Analysis of:Egrifta Becomes the First Agent Approved for HIV-Associated Lipodystrophy | www.thebody.com

Egrifta was evaluated in two clinical trials. 816 HIV infected adults with lipodystrophy and excess abdominal fat. 543 patients received Egrifta. In both studies, patients treated with Egrifta experienced greater reductions in abdominal fat (15-17%) measured by CT scan, vs. placebo. . The most commonly reported side effects in the studies included joint pain (arthralgia), skin redness and rash at the injection site (erythema and pruritis), stomach pain, swelling, and muscle pain (myalgia).

Peter BornsteinEpidemiologist HEALTHEAST CARE SYSTEM

Exodus to where?

May 28, 2010

For physicians to exodus from government programs, they must have someplace to go to. The practice style and location of physicians will dictate whether they stay or leave government programs. Some physicians will find they cannot leave government programs, so will either have to accept lower payment; close, sell or merge their practice; or leave medical practice altogether.

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

Algeta Begins Enrolling Patients in Prostate Cancer Study

December 21, 2009

Analysis of:Algeta begins phase-III trial of Alpharadin in male patient with castration-resistant prostate cancer | www.pharmabiz.com

The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study is a double-blind, randomized, controlled trial that enrols patients to be randomized to receive Alpharadin (radium-223 chloride) plus best standard of care or placebo plus best standard of care.  Approximately 750 patients are expected to be enrolled in this multi-institution trial with. recruitment expected to be complete by the second half of 2010. The primary outcome to be measured is overall survival.

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

An Overall Survival Benefit In Chronic Lymphocytic Leukemia (CLL)

December 10, 2009

Analysis of:Roche presents pivotal phase-III study of CLL8 at ASH 2009 | www.pharmabiz.com

The CLL8 Trial demonstrated that FCR (Fludarabine, Cyotxan, Rituxan) provided a modest, but statistically significant survival benefit over FC (Fludarabine, Cytoxan) in patients with chronic lymphocytic leukemia.

Jeffrey BubisPartner, Hematologist and Medical OncologistINTEGRATED COMMUNITY ONCOLOGY NETWORK, LLC

CCL8 Data Coming to ASH

December 8, 2009

Analysis of:Roche to present CLL8's pivotal phase-III study results at ASH in New Orleans | www.pharmabiz.com

Updated results from the CCL8 trial of Fludarabine and Cytoxan (FC) vs. Fludarabine, Cytoxan, and Rituxan (FCR) will be released at the American Society of Hematology Meeting (ASH) in New Orleans.

Page : 12345678910Next1 to 10 of 173